Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
21 hedge funds and large institutions have $7.06M invested in Soleno Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 7 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
18% more capital invested
Capital invested by funds: $6M → $7.06M (+$1.06M)
3.45% more ownership
Funds ownership: 37.15% → 40.6% (+3.5%)
19% less funds holding
Funds holding: 26 → 21 (-5)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$2.7M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$353K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$214K |
| 4 |
JP Morgan Chase
New York
|
+$157K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$67.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$91K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$39.5K |
| 3 |
E
Ergoteles
New York
|
-$24.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11.5K |
SLNO Hedge Fund Activity: Q1 2023 in Review
21 of the 6,279 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2023, worth a combined $7.06M — up 18% from $6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SLNO and 3 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Carlyle Group, opening a new position worth an estimated $2.7M. The largest seller was Millennium Management, exiting entirely with an estimated $91K sold.
- 21 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2023, down from 26 in Q4 2022.
- Funds reported $7.06M of Soleno Therapeutics stock for Q1 2023, up 18% quarter-over-quarter.
- 3 funds opened new Soleno Therapeutics positions in Q1 2023 and 7 closed out, a net change of -4 holders.
- The largest Soleno Therapeutics buyer in Q1 2023 was Carlyle Group, an estimated $2.7M added.
- The largest Soleno Therapeutics seller in Q1 2023 was Millennium Management, an estimated $91K sold.
Based on aggregated 13F filings for Q1 2023.